Rapid Medical’s Tigertriever 25 Cleared by FDA to Treat LVO Stroke

April 16, 2026—Rapid Medical announced FDA clearance of the Tigertriever 25 thrombectomy device.

Stereotaxis to Acquire Robocath

April 15, 2026–Stereotaxis, a St. Louis, Missouri–based company focused on robotics for endovascular intervention, announced that it has entered into a definitive agreement to acquire Robocath.

Imperative Care Initiates ADAPT 2.0 Study of Zoom System for Acute Ischemic Stroke

April 14, 2026—Imperative Care announced that the initial patients have been enrolled in the ADAPT 2.0 clinical study of continuous dual aspiration using the company’s Zoom system for acute ischemic stroke.

Route 92 Medical Raises Financing to Support Neurovascular Intervention Portfolio

April 7, 2026—Route 92 Medical, Inc., a privately held medical technology company focused on neurovascular intervention, announced a $50 million growth financing.

Serenity Medical Gains FDA Humanitarian Device Exemption for River Cerebral Venous Stent

April 1, 2026—Serenity Medical announced that the United States FDA has granted Humanitarian Device Exemption (HDE) approval for the River stent for the treatment of severe idiopathic intracranial hypertension (IIH) in adult patients who have failed medical therapy.

MicroPort NeuroScientific Apollo Dream Sirolimus Target-Eluting Stent Granted FDA Breakthrough Device Designation

March 31, 2026—MicroPort NeuroScientific Corporation announced that the company’s Apollo Dream sirolimus target-eluting stent system has been granted FDA Breakthrough Device designation.

XCath Iris Surgical Robotic System Used in First Telerobotic Stroke Procedure

March 25, 2026—XCath, a developer of neuroendovascular surgical robotics, announced the completion of the first telerobotic stroke procedure with the XCath Iris surgical robotic system in a clinical investigation termed Operation Robo Angel.

Peijia Medical’s DCwire Micro Guidewire Receives FDA Clearance

March 20, 2026—Peijia Medical, a China-based domestic medical device company focused on transcatheter valve therapeutics and neurovascular intervention markets, announced that its DCwire micro guidewire has received FDA 510(k) clearance.

Imperative Care’s Stroke and Vascular Thrombectomy Portfolio Supported by New Financing

March 18, 2026—Imperative Care, Inc., a developer of treatments for thromboembolic disease, announced the closing of a $100 million convertible note financing.

Perfuze’s Millipede88 Aspiration Catheter Cleared by FDA

March 17, 2026—Perfuze, an Ireland-based developer of catheters for interventional stroke care, announced it has received FDA 510(k) clearance for the Millipede88 aspiration catheter in mechanical neurovascular thrombectomy.

Toro Neurovascular’s Toro 88 Superbore Catheter Cleared by FDA 

March 11, 2026—Toro Neurovascular announced FDA 510(k) clearance and commercial introduction of the Toro 88 superbore catheter, a neurovascular access catheter platform.

Medtronic to Acquire Scientia Vascular

March 10, 2026—Medtronic announced it has entered into a definitive agreement to acquire Scientia Vascular, a developer of access products for the treatment of complex neurovascular conditions.

Route 92 Begins SUMMIT RISE Postmarket Study of its Neurovascular Interventional Portfolio

March 9, 2026—Route 92 Medical, Inc. announced the commencement of the SUMMIT RISE postmarket study evaluating the performance of the company’s portfolio of neurovascular interventional solutions across a variety of stroke scenarios and vessel sizes.

FIH Study Begins for VS3 Medical Stent System for Symptomatic Venous Sinus Stenosis

March 9, 2026—VS3 Medical, Inc. announced it has commenced enrollment in an international first-in-human (FIH) study evaluating the VS3 Medical stent system for patients with symptomatic venous sinus stenosis.

INSYTE Trial Begins for Spryte’s Neuro OCT Imaging System for Intracranial Aneurysm Procedures

March 4, 2026—Spryte Medical announced the commencement of enrollment in the INSYTE trial evaluating the company’s neuro-optical CT (nOCT) imaging system.

CereVasc eShunt System Studied in Treatment of Patients with NPH

February 26, 2026—CereVasc, Inc. announced results from a prospective, multicenter, single-arm clinical study evaluating the safety and clinical outcomes of the eShunt system in patients with normal pressure hydrocephalus (NPH).

J&J MedTech Launches Cereglide 42 and 57 Aspiration Catheters for Stroke

February 26, 2026—Johnson & Johnson MedTech announced the United States launch of the Cereglide 42 and Cereglide 57 aspiration catheters and the Innerglide 7 delivery aid as part of its aspiration-first stroke portfolio.

Bayer’s Asundexian Reduced Recurrent Ischemic Stroke in OCEANIC-STROKE

February 19, 2026—Bayer recently reported that its oral factor XIa inhibitor asundexian reduced the risk of recurrent ischemic stroke in patients after noncardioembolic ischemic stroke or high-risk transient ischemic attack (TIA), meeting the primary efficacy endpoint of the phase 3 OCEANIC-STROKE trial, according to the company’s announcement.

Sentante Enters FDA TAP Program for Remote Stroke System

February 18, 2026—Sentante announced that its Sentante stroke system has been accepted into the FDA Total Product Life Cycle Advisory Program (TAP), building on the Breakthrough Device designation granted in September 2025 and advancing the company’s regulatory pathway toward first-in-human remote stroke trials.

Vesalio Announces CE Mark Approval for NeVa VS and NeVa 3.0 mm

February 10, 2026—Vesalio announced CE Mark certification and the European commercial launch of its NeVa VS for cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH) and NeVa 3.0 mm thrombectomy system for stroke, along with an additional FDA 510(k) clearance expanding indications for its neurovascular and peripheral aspiration catheters to include distal access, according to the company’s press release.